COX-2 Inhibition: A Possible Role in the Management of Prostate Cancer?

References

• Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splic-ing. Proc Natl Acad Sci U S A. 1991; 88: 2692–6.
   PubMed Web of Science ®Google Scholar
• Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991; 266: 12866-72.
   Google Scholar
• Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998; 38: 97–120.
   PubMed Web of Science ®Google Scholar
• Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and thera-peutic implications. Fundam Clin Pharmacol. 1996; 10: 1–17.
   PubMed Web of Science ®Google Scholar
• Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC: Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol. 1999; 31: 551–7.
   PubMed Web of Science ®Google Scholar
• Giercksky KE: COX-2 inhibition and prevention of can-cer. Best Pract Res Clin Gastroenterol. 2001; 15: 821–33.
   PubMed Web of Science ®Google Scholar
• Taketo MM: Cyclooxygenase-2 inhibitors in tumorigene-sis (part I). J Natl Cancer Inst. 1998; 90: 1529-36.
   Google Scholar
• Wright JM: The double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002; 167: 1131–7.
   PubMed Web of Science ®Google Scholar
• Kismet K, Akay MT, Abbasoglu 0, Ercan A: Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prey. 2004; 28: 127–42.
   PubMedGoogle Scholar
• Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. Faseb J. 1998; 12: 1063–73.
   PubMed Web of Science ®Google Scholar
• Hawkey CJ: COX-2 inhibitors. Lancet. 1999; 353: 307–14.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343: 1520–8, 2 p following 1528.
   PubMed Web of Science ®Google Scholar
• Choi HK, Seeger JD and Kuntz KM: Effects of rofecox-ib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. Am J Med. 2004; 116: 621–9.
   PubMed Web of Science ®Google Scholar
• Fitzgerald GA: Coxibs and cardiovascular disease. N Engl J Med. 2004; 351: 1709–11.
   Google Scholar
• Brater DC, Harris C, Redfern JS, Gertz BJ: Renal effects of COX-2-selective inhibitors. Am J Nephrol. 2001; 21: 1–15.
   PubMed Web of Science ®Google Scholar
• del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001; 44: 2737–45.
   PubMed Web of Science ®Google Scholar
• Scott DG, Watts RA: Increased risk of cardiovascular events with coxibs and NSAIDs. Lancet. 2005; 365: 1537.
   PubMedGoogle Scholar
• Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284: 1247–55.
   Google Scholar
• Farkouh ME, Kirshner H, Harrington RA, et al.:Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised con-trolled trial. Lancet. 2004; 364: 675–84.
   PubMed Web of Science ®Google Scholar
• Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364: 2021–9.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Campen D, Hui R, et al: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005; 365: 475–81.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366.
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092–102.
   PubMed Web of Science ®Google Scholar
• Hudson M, Richard H, Pilote L: Differences in out-comes of patients with congestive heart failure prescribed cele-coxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ. 2005; 330: 1370.
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, et al: Complications of the COX-2 inhibitors parecoxib and valde-coxib after cardiac surgery. N Engl J Med. 2005; 352: 1081–91.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 1071–80.
   PubMed Web of Science ®Google Scholar
• Medicines CoSo: 2005. http://www.mca.gov.uk/aboutagency/regframework/csm/csmhome.htm.
   Google Scholar
• Agency EM: http://www.emea.eu.int.
   Google Scholar
• Agency MaHpR: http://www.mhra.gov.uk.
   Google Scholar
• Tseng WW, Deganutti A, Chen MN, Saxton RE, Liu CD: Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg. 2002; 6: 838–43; discussion 844.
   PubMed Web of Science ®Google Scholar
• Kern MA, Schubert D, Sahi D, et al: Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology. 2002; 36: 885–94.
   PubMed Web of Science ®Google Scholar
• Nam DH, Park K, Park C, et al.: Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol Rep. 2004; 11: 263–8.
   PubMed Web of Science ®Google Scholar
• Habel LA, Zhao W, Stanford JL: Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control. 2002; 13: 427–34.
   PubMed Web of Science ®Google Scholar
• Nelson JE, Harris RE: Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep. 2000; 7: 169–70.
   PubMed Web of Science ®Google Scholar
• Platz EA, Rohrmann S, Pearson JD, et al: Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prey. 2005; 14: 390–6.
   PubMed Web of Science ®Google Scholar
• Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammato-ry drugs and prostate cancer incidence. J Natl Cancer Inst. 2005; 97: 975–80.
   PubMed Web of Science ®Google Scholar
• Taketo MM: Cyclooxygenase-2 inhibitors in tumorigen-esis (Part II). J Natl Cancer Inst. 1998; 90: 1609-20.
   Google Scholar
• Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000; 42: 73–8.
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 2000; 89: 589–96.
   PubMed Web of Science ®Google Scholar
• Madaan S, Abel PD, Chaudhary KS, et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int. 2000; 86: 736–41.
   PubMed Web of Science ®Google Scholar
• Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P: Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res. 2001; 29: 23–8.
   PubMedGoogle Scholar
• Badawi AF: The role of prostaglandin synthesis in prostate cancer. BJU Int. 2000; 85: 451–62.
   Google Scholar
• Chaudry AA, Wahle KW, McClinton S, Moffat LE: Arachidonic acid metabolism in benign and malignant prostat-ic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer. 1994; 57: 176–80.
   PubMed Web of Science ®Google Scholar
• Rubenstein M, Shaw MW, McKiel CF, Ray PS, Guinan PD: Immunoregulatory markers in rats carrying Dunning R3327 H, G, or MAT-LyLu prostatic adenocarcinoma vari-ants. Cancer Res. 1987; 47: 178–82.
   PubMed Web of Science ®Google Scholar
• Zha S, Gage WR, Sauvageot J, et al: Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 2001; 61: 8617-23.
   Google Scholar
• Shappell SB, Manning S, Boeglin WE, et al.: Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia. 2001; 3: 287–303.
   PubMed Web of Science ®Google Scholar
• Kirschenbaum A, Klausner AP, Lee R, et al: Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology. 2000; 56: 671–6.
   PubMed Web of Science ®Google Scholar
• Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM: HER2 and COX2 expression in human prostate cancer. Eur J Cancer. 2004; 40: 50–5.
   PubMed Web of Science ®Google Scholar
• Wang W, Bergh A, Damber JE: Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res. 2005; 11: 3250-6.5°
   Google Scholar
• O'Byrne KJ, Dalgleish AG: Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001; 85: 473–83.
   PubMed Web of Science ®Google Scholar
• Nelson WG, De Marzo AM, Isaacs WB: Prostate can-cer. N Engl J Med. 2003; 349: 366–81.
   PubMed Web of Science ®Google Scholar
• Hayes RB, Pottern LM, Strickler H, et al.: Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer. 2000; 82: 718–25.
   PubMed Web of Science ®Google Scholar
• Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG: C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int. 2005; 95: 961–2.
   PubMed Web of Science ®Google Scholar
• Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD: Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost. 2004; 92: 185–90.
   PubMed Web of Science ®Google Scholar
• Nelson WG, DeWeese TL, DeMarzo AM: The diet, prostate inflammation, and the development of prostate can-cer. Cancer Metastasis Rev. 2002; 21: 3–16.
   PubMed Web of Science ®Google Scholar
• Irani J, Goujon JM, Ragni E, et al: High-grade inflam-mation in prostate cancer as a prognostic factor for biochemi-cal recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology. 1999; 54: 467–72.
   PubMed Web of Science ®Google Scholar
• Wang W, Bergh A, Damber JE: Chronic inflammation in benign prostate hyperplasia is associated with focal upregu-lation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004; 61: 60–72.
   PubMed Web of Science ®Google Scholar
• Montironi R, Bostwick DG, Bonkhoff H, Cockett AT, Helpap B, Troncoso P and Waters D: Origins of prostate can-cer. Cancer. 1996; 78: 362–5.
   PubMed Web of Science ®Google Scholar
• Kirschenbaum A, Liu X, Yao S, Levine AC: The role of cyclooxygenase-2 in prostate cancer. Urology. 2001; 58: 127–31.
   PubMed Web of Science ®Google Scholar
• Sabichi AL, Lippman SM: COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer.Semin Oncol. 2004; 31: 36–44.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet. 2001; 357: 539-45.
   Google Scholar
• Luo JC, Shin VY, Yang YH, et al: Tumor necrosis fac-tor-alpha stimulates gastric epithelial cell proliferation. Am J Physiol Gastrointest Liver Physiol. 2005; 288: G32–8.
   PubMed Web of Science ®Google Scholar
• Yucel-Lindberg T, Brunius G, Wondimu B, Anduren I, Modeer T: Enhanced cyclooxygenase-2 mRNA expression in human gingival fibroblasts induced by cell contact with human lymphocytes. Eur J Oral Sci. 2001; 109: 187–92.
   PubMed Web of Science ®Google Scholar
• Marnett LJ: Oxyradicals and DNA damage. Carcinogenesis. 2000; 21: 361–70.
   Google Scholar
• Sun XY, Donald SP, Phang JM: Testosterone and prostate specific antigen stimulate generation of reactive oxy-gen species in prostate cancer cells. Carcinogenesis. 2001; 22: 1775–80.
   PubMed Web of Science ®Google Scholar
• Crocitto LE, Korns D, Kretzner L, et al: Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology. 2004; 64: 821–5.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000; 100: 57–70.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18: 4–25.
   PubMed Web of Science ®Google Scholar
• Fujita H, Koshida K, Keller ET, et al: Cyclooxygenase-2 promotes prostate cancer progression. Prostate. 2002; 53: 232-40.7°
   Google Scholar
• Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC: Inhibition of cyclooxygenase-2 suppresses angio-genesis and the growth of prostate cancer in vivo. J Urol. 2000; 164: 820–5.
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000; 60: 1306–11.
   PubMed Web of Science ®Google Scholar
• Krajewska M, Krajewski S, Banares S, et al.: Elevated expression of inhibitor of apoptosis proteins in prostate can-cer. Clin Cancer Res. 2003; 9: 4914–25.
   PubMed Web of Science ®Google Scholar
• Tanji N, Kikugawa T, Yokoyama M: Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression. Anticancer Res. 2000; 20: 2313–9.
   PubMed Web of Science ®Google Scholar
• Liu XH, Yao S, Kirschenbaum A, Levine AC: N5398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 1998; 58: 4245–9.
   PubMed Web of Science ®Google Scholar
• Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000; 275: 11397-403.
   Google Scholar
• Nguyen KH: NSAID use confers a survival advantage for prostate cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2004; 2182: S445–6.
   Google Scholar
• Wechter WJ, Leipold DD, Murray ED, Jr., et al: E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res. 2000; 60: 2203–8.
   PubMed Web of Science ®Google Scholar
• Swabb EA, Quiggle DD, Gutierrez I, et al.: Multi-dose phase 1 trial of MPC-7869 in prostate cancer patients with increasing prostate specific antigen (PSA). Proc Am Assoc Cancer Res. 2002; 43: 749 (Abstract 3714).
   Google Scholar
• Piazza GA, Rahm AL, Krutzsch M, et al.: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 1995; 55: 3110–6.
   PubMed Web of Science ®Google Scholar
• Mahmoud NN, Boolbol SK, Dannenberg AJ, et al: The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenoma-tous polyposis. Carcinogenesis. 1998; 19: 87–91.
   PubMed Web of Science ®Google Scholar
• Zhang X, Morham SG, Langenbach R, Young DA: Malignant transformation and antineoplastic actions of nons-teroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med. 1999; 190: 451–59.
   PubMed Web of Science ®Google Scholar
• Patel MI, Subbaramaiah K, Du B, et al: Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res. 2005; 11: 1999-2007, 2005.
   Google Scholar
• Song X, Lin HP, Johnson AJ, et al: Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst. 2002; 94: 585–91.
   PubMed Web of Science ®Google Scholar
• Grosch S, Maier TJ, Schiffmann S, Geisslinger G: Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006; 98: 736–47.
   PubMed Web of Science ®Google Scholar
• Dawson NA, Slovin SF: Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer. Urology. 2003; 62 Suppl 1: 102–18.
   PubMedGoogle Scholar
• Derksen JE, Pruthi RS: COX-2 inhibitors in PSA recur-rent prostate cancer: a pilot study. J Urol. 2002; 167 (Suppl): 304 (Abstract 1199).
   Google Scholar
• Pruthi RS, Derksen E, Gaston K: Cyclooxygenase-2 as a potential target in the prevention and treatment of genitouri-nary tumors: a review. J Urol. 2003; 169: 2352–9.
   PubMed Web of Science ®Google Scholar
• Lin DW, Nelson PS: The role of cyclooxygenase-2 inhi-bition for the prevention and treatment of prostate carcinoma. Clin Prostate Cancer. 2003; 2: 119–26.
   PubMedGoogle Scholar